Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;11(2):45-54.
doi: 10.14740/wjon1245. Epub 2020 Mar 29.

Recent Advances in the Management of Smoldering Multiple Myeloma

Bhaskara Reddy Madhira  1 , Venu Madhav Konala  2 , Sreedhar Adapa  3 , Srikanth Naramala  4 , Pavan Mahendra Ravella  5 , Kaushal Parikh  6 , Teresa C Gentile  7
Affiliations
Review

Recent Advances in the Management of Smoldering Multiple Myeloma

Bhaskara Reddy Madhira et al. World J Oncol. 2020 Apr.

Abstract

There is remarkable progress in the treatment of multiple myeloma (MM) with significant improvement in survival in the past 10 years. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) can evolve into symptomatic multiple myeloma (sy-MM) with organ involvement. SMM has associated with a much higher progression to MM compared to MGUS. In 2014, International Myeloma Working Group (IMWG) reclassified ultra-high-risk smoldering myeloma patients with bone marrow plasma cells > 60% or serum-free light chain ratio (FLCr) > 100 or > 1 focal bone lesion on the magnetic resonance imaging as MM. SMM is a heterogeneous disorder with probability for progression to myeloma up to 50% in the first 5 years. Several risk models and clinical features have been identified to stratify the risk of progression to MM. Thanks to advances in our understanding of the genomic profile of MM, there are several ongoing clinical trials, and genomic studies are being done to assess the risk of progression to MM and early intervention. There is still no standard criterion regarding when to start therapy. This review discusses identifying SMM patients who are at high risk of progression to sy-MM and recent development of new and early treatment strategies and ongoing clinical trials for these high-risk SMM patients.

Keywords: Diagnostic criteria; Multiple myeloma; Risk stratification; Smoldering multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The author declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324–339. doi: 10.1016/S0140-6736(09)60221-X. - DOI - PubMed
    1. Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, Hashmi SK. et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6(10):e486. doi: 10.1038/bcj.2016.100. - DOI - PMC - PubMed
    1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–548. doi: 10.1016/S1470-2045(14)70442-5. - DOI - PubMed
    1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–1873. doi: 10.1056/NEJMra041875. - DOI - PubMed
    1. Rago A, Grammatico S, Za T, Levi A, Mecarocci S, Siniscalchi A, De Rosa L. et al. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. Cancer. 2012;118(22):5544–5549. doi: 10.1002/cncr.27657. - DOI - PubMed

LinkOut - more resources